Patents by Inventor Giuseppe Alvaro

Giuseppe Alvaro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoMethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2 as NK1 receptor antagonists
    Patent number: 8344005
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C1-4 alkyl useful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: January 1, 2013
    Assignee: Glaxo Wellcome Manufacturing Pte Ltd
    Inventors: Giuseppe Alvaro, Agostino Marasco
  • IMIDAZOLIDINEDIONE DERIVATIVES
    Publication number: 20120289526
    Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizophrenia, substance abuse disorders, sleep disorders or epilepsy.
    Type: Application
    Filed: December 6, 2010
    Publication date: November 15, 2012
    Inventors: Giuseppe Alvaro, Anne Décor, Stefano Fontana, Dieter Hamprecht, Charles Large, Agostino Marasco
  • PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20120095034
    Abstract: This invention relates to imidazo[1,2-a]pyridin-2-ylmethyl substituted piperidine derivatives of formula (I) and their use as pharmaceuticals, in the treatment of obesity and diabetes.
    Type: Application
    Filed: July 1, 2008
    Publication date: April 19, 2012
    Inventors: Giuseppe Alvaro, David Amantini, Sandro Bel Vedere
  • Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide
    Patent number: 8153681
    Abstract: The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels. Methods of treating epilepsy in a mammal are also provided.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: April 10, 2012
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Giuseppe Alvaro, Markus Bergauer, Roberto Profeta, Riccardo Giovannini
  • Compounds
    Patent number: 8153623
    Abstract: Compounds of formula (I), pharmaceutical compositions thereof, and methods for treatment using the same.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: April 10, 2012
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Giuseppe Alvaro, David Amantini, Markus Bergauer, Francesca Bonetti, Roberto Profeta
  • Methods of treating bipolar disorders
    Patent number: 8143306
    Abstract: The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels. Methods of treating and moderating one or more bipolar disorders in a mammal are also provided.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: March 27, 2012
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Giuseppe Alvaro, Markus Bergauer, Roberto Profeta, Riccardo Giovannini
  • Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine
    Patent number: 8133908
    Abstract: Disclosed are N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives having the following formula: wherein m, n, Het, R1, R2 and R3 are as defined herein, and their use as orexin antagonists.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: March 13, 2012
    Assignee: Glaxo Group Limited
    Inventors: Giuseppe Alvaro, David Amantini, Emiliano Castiglioni, Romano Di Fabio, Francesca Pavone
  • Imidazo[1,2-a]pyrazines as orexin receptor antagonists
    Patent number: 8129384
    Abstract: This invention relates to imidazopyrazine substituted piperidine derivatives and their use as pharmaceuticals.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: March 6, 2012
    Assignee: Glaxo Group Limited
    Inventors: Giuseppe Alvaro, David Amantini, Sandro Belvedere
  • Pyridine derivatives and their use in the treatment of psychotic disorders
    Patent number: 8097618
    Abstract: A method of treatment of anxiety disorders which comprises administering to a host in need thereof an effective amount of a compound of formula (I):
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: January 17, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Giuseppe Alvaro, Sandro Belvedere
  • Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
    Patent number: 8093268
    Abstract: The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl-piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.
    Type: Grant
    Filed: January 21, 2008
    Date of Patent: January 10, 2012
    Assignee: Glaxo Group Limited
    Inventors: Giuseppe Alvaro, Charles Large
  • Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
    Patent number: 8093255
    Abstract: This invention relates to imidazopyrimidine substituted piperidine derivatives and their use as pharmaceuticals.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: January 10, 2012
    Assignee: Glaxo Group Limited
    Inventors: Giuseppe Alvaro, David Amantini, Sandro Belvedere
  • NOVEL COMPOUNDS
    Publication number: 20110288098
    Abstract: This invention relates to imidazopyrazine substituted piperidine derivatives and their use as pharmaceuticals.
    Type: Application
    Filed: August 2, 2011
    Publication date: November 24, 2011
    Inventors: Giuseppe ALVARO, David Amantini, Sandro Belvedere
  • PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS
    Publication number: 20110257198
    Abstract: Disclosed are imidazopyridylmethylene substituted piperidine derivatives of Formula (I): useful as orexin antagonists.
    Type: Application
    Filed: December 21, 2009
    Publication date: October 20, 2011
    Inventors: Giuseppe Alvaro, David Amantini
  • Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders
    Publication number: 20110190276
    Abstract: A method of treatment of anxiety disorders which comprises administering to a host in need thereof an effective amount of a compound of formula (I):
    Type: Application
    Filed: February 23, 2011
    Publication date: August 4, 2011
    Inventors: Giuseppe Alvaro, Sandro Belvedere
  • NOVEL COMPOUNDS
    Publication number: 20110098335
    Abstract: The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.
    Type: Application
    Filed: January 4, 2011
    Publication date: April 28, 2011
    Applicant: Convergence Pharmaceuticals Limited
    Inventors: Giuseppe Alvaro, Markus Bergauer, Roberto Profeta, Riccardo Giovannini
  • Pyridine derivatives and their use in the treatment of psychotic disorders
    Patent number: 7919491
    Abstract: A pyridine derivative novel compounds of formula (I) or a pharmaceutically acceptable salt thereof where all variables are defined herein. The compounds are useful in the treatment of psychotic disorders.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: April 5, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Giuseppe Alvaro, Sandro Belvedere
  • 5-[5-[2-(3,5-BIS(Trifluoromethyl)Phenyl)-2-MethylpropanoMethylpropanoylmethylamino]-4-(4-Fluoro-2-Methylphenyl)]-2-Pyridinyl-2-Alkyl-Prolinamide As NK1 Receptor Antagonists
    Publication number: 20110060015
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C1-4 alkyl useful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.
    Type: Application
    Filed: May 12, 2009
    Publication date: March 10, 2011
    Inventors: Giuseppe Alvaro, Agostino Marasco
  • PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS
    Publication number: 20110053979
    Abstract: This invention relates to pyridinamine methyl substituted piperidinyl derivatives I and their use as pharmaceuticals.
    Type: Application
    Filed: April 8, 2009
    Publication date: March 3, 2011
    Inventors: Giuseppe Alvaro, David Amantini, Luigi Piero Stasi
  • Spiro (Piperidine-4,2'-Pyrrolidine)-1-(3,5-Trifluoromethyl Phenyl) Methylcarboxamides As NK1 Tachikynin Receptor Antagonists
    Publication number: 20110053922
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R is hydrogen or C1-4 alkyl; R1 is hydrogen, C1-4 alkyl, C(O)OH, C(O)NH2 or (C1-4 alkylene)R10; R2 and R3 are independently hydrogen, C1-4 alkyl or R2 together with R3 and together with the carbon atom to which they are attached form a C3-8 cycloalkyl group; R4 is C1-4 alkyl, C1-4 alkoxy or halogen; R5 and R7 are independently hydrogen, hydroxy, halogen, C(O)NH2, C(O)OH or (C1-4 alkylene) R10; R6 and R8 are independently hydrogen or halogen; R9 is hydrogen, (C1-4 alkylene)R10, C(O)NH2, C(O)OH or R9 together with R form a 6 membered heterocyclic ring optionally containing a further heteroatom selected from oxygen, sulphur or nitrogen; R10 is hydrogen, halogen, hydroxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2 or C(O)OH; n is 0, 1 or 2. processes for their preparation, to compositions containing them and to their use in the treatment of diseases and conditions for which antagonism of NK1 is beneficial.
    Type: Application
    Filed: April 29, 2009
    Publication date: March 3, 2011
    Inventors: Giuseppe Alvaro, Emiliano Castiglioni, Agostino Marasco
  • NOVEL COMPOUNDS
    Publication number: 20100324022
    Abstract: Compounds of formula (I), pharmaceutical compositions thereof, and methods for treatment using the same.
    Type: Application
    Filed: August 4, 2010
    Publication date: December 23, 2010
    Applicant: GLAXO GROUP LIMITED
    Inventors: Giuseppe Alvaro, David Amantini, Markus Bergauer, Francesca Bonetti, Roberto Profeta